These results indicated that TAZ enhanced the sensitivity of EGFR wild-type NSCLC cells to gefitinib by facilitating the phosphorylation of Akt, ERK1/2 and EGFR. The gene discussed is MAPK3; the disease is non-small cell lung carcinoma.